Fibronostics Corporate Update

Fibronostics Presents Corporate Update at TKS 1 Investor Day in Singapore

ORLANDO, Fla – February 27, 2019 – Fibronostics, a healthcare technology company providing algorithm-based solutions for diagnostic testing, presented its corporate strategy at the second annual TKS 1 Investor Day in Singapore. The event was attended by current and potential investors in the TKS 1 fund, including venture capitalists, strategic investors, family offices and leaders from the healthcare industry.

Fibronostics is in the final stages of negotiations with partner companies in retail health, consumer and corporate wellness, clinical trial recruitment and concierge medicine. These potential partnerships are in addition to commercial agreements executed last year.

“Fibronostics had a very successful 2018, posting strong business growth in existing markets in Asia, establishing the company in the US market, and building significant momentum,” said Brett Giffin, CEO of Fibronostics. “In 2019, we’re very well positioned for continued growth, and we’re excited about our impending market launches in Europe and South America, as well.”

Fibronostics algorithm-based solutions focus on assessing liver disease existence and progression, but also other chronic areas such as coronary heart disease, stroke, diabetes, and obstructive sleep apnea. The LiverFASt and HealthFACTR family of tests quickly and accurately analyze blood biomarker data with digital results, providing rapid and inexpensive early alerts well before a patient’s condition demands the expense and risk of invasive procedures.  

Liver health, especially nonalcoholic steatohepatitis (NASH), is a growing problem around the world, and it’s estimated as many as 30 million people suffer with the disease in the U.S. alone. According to the Center for Disease Analysis, this costs the U.S. $5 billion in healthcare costs annually and is contributing to a rapidly expanding market for new treatments and diagnostics of the disease.

The Investor Day event in Singapore was hosted by SPRIM Ventures and Tikehau Capital (TKO.FP) on behalf of their venture capital fund TKS 1. TKS 1 provides early-stage capital to innovative companies offering solutions that move science forward in the health sector. Fibronostics was seeded by TKS 1 in 2017.

Tikehau Capital is an alternative asset management and investment group with €15.9 billion of assets under management (as of 30 September 2018) and shareholders’ equity of €2.3 billion (as of 30 June 2018). The group invests in various asset classes (private debt, real estate, private equity, and liquid strategies), including through its asset management subsidiary Tikehau IM, on behalf of institutional and private investors. Controlled by its managers, alongside leading institutional partners, Tikehau Capital employs 260 staff (as of 30 September 2018) in its Paris, London, Brussels, Madrid, Milan, New York, Seoul and Singapore offices.

SPRIM Ventures is a venture arm of SPRIM, a life-science consulting agency focused on innovation in human health, providing services for the full lifecycle of a product or business. Multi-nationals, startups, institutions, and governments around the world turn to SPRIM for expertise in developing relevant, fresh and meaningful health innovations.